World's richest 10% caused two-thirds of global warming: study
The world's wealthiest 10 percent of individuals are responsible for two-thirds of global warming since 1990, researchers said on Wednesday.
How the rich consume and invest has substantially increased the risk of deadly heatwaves and drought, they reported in the first study to quantify the impact of concentrated private wealth on extreme climate events.
"We link the carbon footprints of the wealthiest individuals directly to real-world climate impacts," lead author Sarah Schoengart, a scientist at ETH Zurich, told AFP.
"It's a shift from carbon accounting toward climate accountability."
Compared to the global average, for example, the richest one percent contributed 26 times more to once-a-century heatwaves, and 17 times more to droughts in the Amazon, according to the findings, published in Nature Climate Change.
Emissions from the wealthiest 10 percent in China and the United States - which together account for nearly half of global carbon pollution - each led to a two-to-threefold rise in heat extremes.
Burning fossil fuels and deforestation have heated Earth's average surface by 1.3 degrees Celsius, mostly during the last 30 years.
Schoengart and colleagues combined economic data and climate simulations to trace emissions from different global income groups and assess their impact on specific types of climate-enhance extreme weather.
The researchers also emphasised the role of emissions embedded in financial investment rather than just lifestyle and personal consumption.
"Climate action that doesn't address the outsized responsibilities of the wealthiest members of society risk missing one of the most powerful levers we have to reduce future harm," said senior author Carl-Friedrich Schleussner, head of the Integrated Climate Impacts Research Group at the International Institute for Applied Systems Analysis near Vienna.
Billionaires' tax
Owners of capital, he noted, could be held accountable for climate impacts through progressive taxes on wealth and carbon-intensive investments.
Earlier research has shown that taxing asset-related emissions is more equitable than broad carbon taxes, which tend to burden those on lower incomes.
Recent initiatives to increase taxes on the super-rich and multinationals have mostly stalled, especially since Donald Trump regained the White House.
Last year, Brazil - as host of the G20 - pushed for a two-percent tax on the net worth of individuals with more than $1 billion in assets.
Although G20 leaders agreed to "engage cooperatively to ensure that ultra-high-net-worth individuals are effectively taxed," there has been no follow-up to date.
In 2021, nearly 140 countries agreed on work toward a global corporate tax for multinational companies, with nearly half endorsing a minimum rate of 15 percent, but those talks have stalled as well.
Almost a third of the world's billionaires are from the United States - more than China, India and Germany combined, according to Forbes magazine.
According to anti-poverty NGO Oxfam, the richest 1 percent have accumulated $42 trillion in new wealth over the past decade.
It says the richest one percent have more wealth than the lowest 95 percent combined.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
38 minutes ago
- Gizmodo
China Set for Critical Orbital Refueling Test With 2 U.S. Satellites Watching Closely
Two Chinese satellites are about to rendezvous in geostationary orbit, docking with one another for an experimental demonstration that could extend the longevity of spacecraft. Shijian-21 and Shijian-25 performed a series of maneuvers this past weekend, reaching a close distance of just two degrees of longitude from one another on Monday, according to space situational awareness company COMSPOC. The pair are set to meet on Wednesday for a docking procedure for China's first on-orbit refueling test in geostationary orbit (GEO), acting like a space gas station to extend the lifespan of satellites. China's satellites aren't alone, however, as two U.S. surveillance spacecraft are lurking nearby to watch it all happen, with the Pentagon fearing the technology could represent a significant milestone in China's space ambitions. The two satellites were developed by the Shanghai Academy of Spaceflight Technology, a subsidiary of the China Aerospace Science and Technology Corporation. Shijian-25 launched in January while Shijian-21 lifted off earlier in 2021. Around a year after its launch, Shijian-21 docked with a defunct Chinese satellite, the Beidou-2 G2 navigation satellite, and towed it to the graveyard orbit above GEO, SpaceNews reported at the time. Since then, Shijian-21 appeared to have run out of fuel—until it recently sprang back to life with maneuvers of its own to get closer to Shijian-25. It's likely the target of the in-orbit refueling test, in which Shijian-25 will attempt to transfer about 313 pounds (142 kilograms) of hydrazine to extend the satellite's life by eight years, according to Universe Today. The refueling test has raised concerns in the U.S. about China's growing space capabilities, prompting officials to closely monitor the situation. Two surveillance satellites, USA 270 and USA 271, part of the Geosynchronous Space Situational Awareness Program, performed maneuvers of their own to approach the vicinity of the Chinese satellites, according to COMSPOC. 'While these U.S. assets aren't directly involved, their proximity adds complexity to the local SSA picture — and raises strategic awareness concerns,' the company wrote on X. The U.S. has previously carried out in-orbit refueling tests of its own. In 2019, Northrop Grumman refueled a satellite in space to extend its lifespan by five years, becoming the first company to do so. The U.S. Space Force is also preparing its own set of orbital refueling tests, known as Tetra-5 and Tetra-6, using hardware from Northrop Grumman and other commercial suppliers. For now, the U.S. will stick to watching its space rival carry out the orbital maneuver from a safe distance.
Associated Press
42 minutes ago
- Associated Press
Chesapeake Bay health grade dips after hottest year on record and extreme rainfall patterns
ANNAPOLIS, Md. (AP) — The health of the Chesapeake Bay declined in an annual report card on the nation's largest estuary released Tuesday, with scientists noting the effect of extreme rainfall patterns during the hottest year on record. The University of Maryland Center for Environmental Science gave the bay a C grade in its report card. That compares to a C-plus grade the bay received last year, which was the highest grade it had received since 2002. 'There was a substantial upturn in the overall Bay Health score in 2024, and it came down a little this year,' said Heath Kelsey, director of UMCES Integration and Application Network. 'Over the long term, though, there is still an improving trend from the 1980s until now. We think extreme weather may have had some impact on the scores this year.' The report noted that last year was the hottest year on record, with extreme rainfall patterns. 'While parts of the watershed experienced drought, brief but intense downpours can cause water to flow over the ground rather than soak into it, increasing the fertilizer, dirt, and debris carried into waterways,' the report said. Bill Dennison, vice president for Science Application at UMCES, said the changing climate is definitely having an effect on the bay. 'One of the things that we saw in Maryland, in particular, was a prolonged summer drought — not so much spring, but a summer drought — punctuated by these extreme runoff events,' Dennison said. 'So what was happening was that the crops didn't have enough water, so they're not soaking up the nutrients.' As a result, when it did rain, there were excess nutrients, like nitrogen and phosphorus, that were flowing into the bay, Dennison said. 'Now sadly, this is kind of our future,' Dennison said at a news conference at the Annapolis Maritime Museum near the bay. 'This is the kind of weather patterns that are starting to become more common, which is drought punctuated by extreme events.' Warmer weather winters and higher temperatures mean less oxygen in the water for aquatic life, stressing fish and shellfish, Dennison added. 'So these are some of the things that we have to overcome and build more resilience into our system,' Dennison said. Despite the grade drop, the report cited long-term improvements in dissolved oxygen in the bay's waters. That's the amount of oxygen present in the water that is needed to support bay aquatic life. The report also noted long-term improvements in aquatic grasses, which provide habitat and food for various species, improve water quality and protect shorelines from erosion. Phosphorus and nitrogen levels also have improved in the long-term in another positive sign. While they are needed by the bay's organisms, excessive nitrogen and phosphorus degrade the bay's water quality. Excess nitrogen and phosphorus fuel algal blooms that can cloud the water and block sunlight from reaching underwater grasses. Water clarity and chlorophyll-a scores, however, have declining long-term trends, the report said. Chlorophyll-a in the bay is an indicator of phytoplankton abundance and water quality. Improving trends can be attributed to management and restoration efforts at the regional, state, and local levels, the report said. Regionally, wastewater treatment plants have been upgraded and programs have been put in place to reduce nutrient and sediment input. The health of the bay is a reflection of what's happening across its six-state watershed, which includes Delaware, Maryland, New York, Pennsylvania, Virginia and West Virginia along with the District of Columbia. UMCES, which is marking its 100th anniversary, also provides a grade for the overall watershed health in its report card. It gave the watershed a grade of C-plus. The watershed health grade includes ecological, societal and economic indicators. The most concerning societal indicator was heat vulnerability, the report said, noting communities may be under heat stress due to hotter air temperatures, less tree canopy cover, and more paved surfaces.
Medscape
an hour ago
- Medscape
Skill Checkup: Woman With Persistent Anemia and Fatigue
A 72-year-old woman presents with persistent anemia and fatigue. Her height is 5 ft 2 in (1.57 m) and weight is 131 lb (59.42 kg; body mass index of 24). She was diagnosed with low- to intermediate-risk myelodysplastic syndrome (MDS) with ring sideroblasts 2 years ago when she presented with unexplained macrocytic anemia. Bone marrow biopsy at the time showed blasts were 5%-7%, and her specimen tested positive for SF3B1 mutation and negative for del(5q) . Her erythropoietin levels were < 400 and she received erythropoiesis-stimulating agent (ESA) therapy, requiring ≥ 2 red blood cell (RBC) units over 8 weeks. However, despite ESA therapy, the patient presents with symptomatic anemia; her hemoglobin is 10.1 g/dL. There are no blasts in the blood; 16% of erythroid precursors with ring sideroblasts are identified. Because this patient's anemia is not responding to treatment, the likely diagnosis is MDS with ESA-refractory anemia. ESAs are a potential therapy for the treatment of patients with MDS. However, most patients with MDS either do not respond to ESAs or eventually will develop resistance to these agents. Progression to acute myeloid leukemia (AML) in myelodysplastic syndrome is defined by the presence of ≥ 20% blasts in the peripheral blood or bone marrow (World Health Organization criteria). In this case, the patient has no blasts in the blood and had 5%-7% blasts at diagnosis, which is consistent with MDS but not AML. Copper deficiency can cause a sideroblastic-like anemia, but it is typically associated with neurologic symptoms (eg, ataxia, paresthesias), leukopenia, and a history of risk factors such as zinc overuse, malabsorption, or gastric surgery. This patient has a known diagnosis of MDS with ring sideroblasts and a pathogenic SF3B1 mutation, strongly supporting a clonal myeloid neoplasm rather than a nutritional deficiency. Although symptomatic anemia is a major morbidity of MDS, the anemia described in the present case, refractory anemia with ring sideroblasts (MDS-RS), is a subtype often associated with SF3B1 mutations, which lead to defective RNA splicing and secondary mitochondrial iron accumulation. This results in the formation of ring sideroblasts. SF3B1 is the most frequently mutated splicing factor gene in MDS-RS, and it is associated with better outcomes and longer survival. In this case, the presence of this mutation confirms a diagnosis of MDS over secondary causes of ring sideroblasts. Anemia in MDS might or might not be symptomatic at presentation and varies in degree, from mild to severe. Clinical symptoms of MDS, including fatigue as described by this patient, arise because of low peripheral blood counts, usually from anemia, but also can occur from thrombocytopenia or neutropenia. Features predictive of ESA response include a lower baseline serum erythropoietin (EPO) level (< 500 IU/mL), a low transfusion burden (< 2 units a month), a fixed-dose regimen, shorter time from diagnosis to starting treatment, and diagnosis of refractory anemia or MDS-RS. Although the patient in the present case is in fact diagnosed with refractory anemia or MDS-RS, response rates to ESA therapy are variable in patients with lower-risk MDS, ranging from 30%-60%. In this patient population, close monitoring of hemoglobin level is recommended to avoid increases to > 12 g/dL (as it is associated with a risk for systemic hypertension and thrombosis). In addition, the immunomodulatory agent lenalidomide can reduce transfusion requirements in patients with lower-risk MDS and a normal karyotype. In MDS, anemia is usually anisocytic, with a normal or a hypochromic microcytic population coexisting with the macrocytes. It is also generally macrocytic (mean cell volume, > 100 fL) with RBCs that are oval-shaped (macro-ovalocytes). Punctate basophilia is observed in RBCs. Symptomatic anemia in MDS frequently presents as a hypoproductive macrocytic anemia, often associated with suboptimal elevation of serum EPO levels. The National Comprehensive Cancer Network (NCCN) guidelines advise that during MDS workup, cytogenetics, bone marrow aspiration with iron stain, biopsy, serum EPO, and other coexisting causes should be ruled out. For MDS to be classified as MDS-RS, as in the present case, anemia should be present but with low blasts in the blood; for bone marrow, either ≥ 15% of erythroid precursors with ring sideroblasts must be identified, or if SF3B1 mutation is present, ≥ 5% ring sideroblasts. The same guidelines also make recommendations for additional testing of symptomatic anemia with MDS. These include flow cytometry to evaluate for large granular lymphocyte and paroxysmal nocturnal hemoglobinuria clone. Human leukocyte antigen typing offers clinical value if the patient is a hematopoietic cell transplant candidate. Because the patient in the present case is considered lower risk, she probably is not at this juncture. Recombinant fusion protein, such as luspatercept, is the most appropriate option for this patient, given its approval for the treatment of anemia in patients with lower-risk MDS-RS who have not responded to treatment with ESAs. In patients with lower-risk MDS and symptomatic anemia, treatment is usually guided by cytogenetic findings, serum EPO levels, and the presence of ring sideroblasts or SF3B1 mutations. For patients with del(5q) , lenalidomide remains the preferred treatment regardless of EPO level. For those with SF3B1 mutations or ring sideroblasts ≥ 15% (or ≥ 5% with a mutation), luspatercept is preferred, with imetelstat recommended if EPO is > 500 mU/mL and the patient is ineligible for ESAs. In patients without these features, ESAs plus granulocyte colony-stimulating factor or imetelstat may be considered on the basis of EPO levels, with follow-up based on response. Escalation to agents like ivosidenib or enasidenib is recommended only in the presence of IDH mutations. Neither hypomethylating agents or allogeneic transplant are included in this lower-risk anemia-focused treatment pathway. Further, intensive induction chemotherapy is not typically utilized in this setting.
